NurExone Biologic Inc.,, a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations.
TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations. With a distinguished background in the pharmaceutical industry, including significant tenure and pivotal roles at Teva Pharmaceuticals, Dr. Petter’s addition signals NurExone’s readiness for industry partnerships and licensing agreements.
Dr. Petter will leverage his experience to support NurExone’s operational activities and facilitate the Company’s strategic engagement in the effort to fully realize NurExone’s potential and maximize its reach. This appointment underscores NurExone’s commitment to fostering innovation and forging impactful commercial partnerships that accelerate the implementation of the Company’s vision for regenerative medicine.
“Our ExoTherapy platform for drug delivery is ready for industry partnerships targeting clinical indications beyond acute spinal cord injury,” says Dr. Lior Shaltiel, CEO of NurExone. “Ram’s extensive experience and strategic acumen will be most helpful in forging these critical collaborations.”
Dr. Petter’s involvement with NurExone does not imply a relationship with Teva Pharmaceuticals.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company entering into industry partnerships and/or licensing agreements; Dr. Petter supporting the Company’s operations and facilitating the Company’s engagement to realize potential and maximize reach; the Company’s products being ready for partnerships; and the NurExone platform technology offering novel solutions to drug companies.
These statements reflect management’scurrent beliefs and are based on information currently available to management as at the date hereof.In developing the forward-looking statements in this press release, we have applied several material assumptions, includingthe general business and economic conditions of the industries and countries in which we operate; the general marketconditions; the ability to secure additional funding; the engagement of Dr. Petter having its intended outcome; the Company entering into new partnerships and/or licensing agreement; and the NurExone platform technology will offer novel solutions to drug companies.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results,performance or achievements to differ materially from the results discussed or implied in the forward-looking statements.These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lackof revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence onkey personnel, protection of the Company’s intellectual property, the Company receiving requisite regulatory approvals, dependence on the Company’s strategic partners and therisks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should beconsidered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-lookingstatements contained in this press release are based upon what management believes to be reasonableassumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements.These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation toupdate or revise them to reflect new events or circumstances, except as required by law.
Neither TSXVenture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracy of this release.
